Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Valneva SE ADR (VALN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: VALN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -30.99% | Avg. Invested days 26 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 548.90M USD | Price to earnings Ratio - | 1Y Target Price 14.28 |
Price to earnings Ratio - | 1Y Target Price 14.28 | ||
Volume (30-day avg) 39790 | Beta 1.11 | 52 Weeks Range 3.62 - 9.50 | Updated Date 04/2/2025 |
52 Weeks Range 3.62 - 9.50 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.17 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-03-18 | When Before Market | Estimate -0.165 | Actual -0.5425 |
Profitability
Profit Margin -7.22% | Operating Margin (TTM) -38.61% |
Management Effectiveness
Return on Assets (TTM) -10.03% | Return on Equity (TTM) -7.91% |
Valuation
Trailing PE - | Forward PE 666.67 | Enterprise Value 594767757 | Price to Sales(TTM) 3.24 |
Enterprise Value 594767757 | Price to Sales(TTM) 3.24 | ||
Enterprise Value to Revenue 3.24 | Enterprise Value to EBITDA 17.13 | Shares Outstanding 81198600 | Shares Floating 118394056 |
Shares Outstanding 81198600 | Shares Floating 118394056 | ||
Percent Insiders - | Percent Institutions 0.87 |
Analyst Ratings
Rating 4.25 | Target Price 15.85 | Buy 1 | Strong Buy 2 |
Buy 1 | Strong Buy 2 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Valneva SE ADR
Company Overview
History and Background
Valneva SE, initially Vivalis SA, was founded in 1999. It merged with Intercell in 2013 to become Valneva. It has focused on developing and commercializing vaccines for infectious diseases.
Core Business Areas
- Travel Vaccines: Development and commercialization of vaccines against diseases affecting travelers, such as Japanese encephalitis (IXIARO) and cholera/ETEC (DUKORAL).
- Emerging Infectious Diseases: Development of vaccines against emerging infectious diseases, including Lyme disease (VLA15) and chikungunya (IXCHIQ).
- Vaccine Manufacturing: Manufacturing vaccines and biologicals for third parties, providing contract manufacturing services.
Leadership and Structure
Valneva SE is led by a management team headed by CEO Thomas Lingelbach. The company has a supervisory board overseeing the management board.
Top Products and Market Share
Key Offerings
- IXIARO/JESPECT (Japanese Encephalitis Vaccine): A vaccine for Japanese encephalitis virus (JEV) infection. Market share varies by region. Competitors include Sanofi Pasteur's IMOJEV. Revenue information is not available publicly but it is a key driver of the travel vaccine portfolio. This segment made 118.6 million Euros in 2023.
- DUKORAL (Cholera/ETEC Vaccine): An oral vaccine for cholera and enterotoxigenic Escherichia coli (ETEC). Market share is difficult to determine precisely. Revenue information is not available publicly but it is a key driver of the travel vaccine portfolio. This segment made 30.5 million Euros in 2023.
- IXCHIQ (Chikungunya Vaccine): The world's first vaccine for Chikungunya, launched at the end of 2023. Competitors are emerging, and market share data is not yet available.
Market Dynamics
Industry Overview
The vaccine industry is characterized by high barriers to entry, significant R&D investments, and stringent regulatory requirements. The market is growing due to increasing awareness of preventative healthcare, emerging infectious diseases, and government initiatives.
Positioning
Valneva is positioned as a specialty vaccine company focused on travel vaccines and emerging infectious diseases. Their competitive advantage lies in their expertise in developing and commercializing vaccines for niche markets.
Total Addressable Market (TAM)
The global vaccine market is estimated to reach hundreds of billions of dollars. Valneva targets specific segments within this market, with a TAM potentially in the billions. It is positioned to capture a growing share of these segments through innovation and strategic partnerships.
Upturn SWOT Analysis
Strengths
- Specialized vaccine portfolio (travel and emerging infectious diseases)
- Established manufacturing capabilities
- First-mover advantage in certain markets (e.g., Chikungunya)
- Strong partnerships with research institutions and government agencies
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Dependence on a few key products
- High R&D costs and regulatory risks
- Reliance on partnerships for funding and distribution
Opportunities
- Expansion into new geographic markets
- Development of new vaccines for emerging infectious diseases
- Strategic acquisitions and collaborations
- Increased government funding for vaccine research and development
Threats
- Competition from larger pharmaceutical companies
- Regulatory hurdles and delays
- Adverse events and product liability claims
- Changes in government policies and reimbursement rates
Competitors and Market Share
Key Competitors
- GSK (GSK)
- Sanofi (SNY)
- Pfizer (PFE)
Competitive Landscape
Valneva faces strong competition from established pharmaceutical companies. Its advantages lie in its specialized focus, innovative products, and first-mover advantage in certain markets.
Major Acquisitions
Intercell AG
- Year: 2013
- Acquisition Price (USD millions):
- Strategic Rationale: Merged to create a leading vaccine company focused on travel and specialty vaccines, expanding product portfolio and geographic reach.
Growth Trajectory and Initiatives
Historical Growth: Valneva's growth has been driven by the commercialization of IXIARO/JESPECT and DUKORAL. Recent growth trajectory also includes IXCHIQ sales.
Future Projections: Future growth is expected to be driven by the launch of new vaccines, particularly VLA15 for Lyme disease, and expansion into new markets. Analyst estimates suggest positive revenue growth over the next few years but still no profit.
Recent Initiatives: Recent strategic initiatives include partnerships for vaccine development and distribution, as well as investments in manufacturing capacity.
Summary
Valneva is a specialty vaccine company with innovative products focused on travel and emerging infectious diseases. Its strengths lie in its specialized portfolio and manufacturing capabilities, but it faces challenges from larger competitors and regulatory hurdles. The company's future growth depends on the successful launch of new vaccines and strategic partnerships. The company is currently burning through cash, so future funding will have to be addressed.
Similar Companies
BNTX
BioNTech SE
BNTX
BioNTech SE
GSK
GlaxoSmithKline PLC ADR
GSK
GlaxoSmithKline PLC ADR
MRNA
Moderna Inc
MRNA
Moderna Inc
PFE
Pfizer Inc
PFE
Pfizer Inc
SNY
Sanofi ADR
SNY
Sanofi ADR
Sources and Disclaimers
Data Sources:
- Valneva SE Investor Relations
- Company SEC Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market data is subject to change. Financial data is based on available public information.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Valneva SE ADR
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-05-05 | President, CEO & Director Mr. Thomas Lingelbach | ||
Sector Healthcare | Industry Biotechnology | Full time employees 713 | Website https://valneva.com |
Full time employees 713 | Website https://valneva.com | ||
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.